Literature DB >> 11081893

Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels.

P Medina1, G Segarra, J B Martínez-León, J M Vila, M Aldasoro, E Otero, S Lluch.   

Abstract

BACKGROUND: Sildenafil is currently used in the treatment of erectile dysfunction. However, assessment of direct effects of sildenafil on coronary arteries and on arteries used as coronary grafts is unknown. This study was designed to investigate the effects of sildenafil on contracted human coronary, internal mammary, and radial arteries obtained from multiorgan donors. The observations were extended to forearm veins. Zaprinast was included in this study for comparison.
METHODS: Segments of left coronary, internal mammary, and radial arteries, and forearm veins were obtained from 16 multiorgan donors. Vascular rings were suspended in organ bath chambers and isometric tension was recorded. Then the effects of sildenafil, zaprinast, and sodium nitroprusside on precontracted vessels were studied.
RESULTS: Sildenafil (10(-8) - 3 x 10(-5) mol/L) caused concentration-dependent relaxation in the internal mammary arteries, radial arteries, and forearm veins. In the coronary arteries, sildenafil had a modest relaxant effect. In addition, sildenafil amplified the relaxation induced by sodium nitroprusside in all four vessels. Relaxation was unaffected by the inhibitor of nitric oxide synthase NG-monomethyl-L-arginine (10(-4) mol/L). Compared with zaprinast, sildenafil was eight to ten times more potent in terms of EC50 values.
CONCLUSIONS: The direct relaxant effects of sildenafil together with its synergistic interaction with nitric oxide donors should be considered in patients undergoing coronary bypass surgery, patients with low blood pressure, and patients receiving antihypertensive regimes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081893     DOI: 10.1016/s0003-4975(00)01914-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

Authors:  Puneeta Tandon; Irteza Inayat; Michael Tal; Marcelo Spector; Martha Shea; Roberto J Groszmann; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-06       Impact factor: 11.382

2.  Inhibition of neuroeffector transmission in human vas deferens by sildenafil.

Authors:  P Medina; G Segarra; B Torondel; P Chuan; C Domenech; J M Vila; S Lluch
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.

Authors:  Ying-Wen Wang; Han-Chieh Lin; Ying-Ying Yang; Ming-Chih Hou; Shou-Dong Lee
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

4.  Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Authors:  Jacob D Peuler; Laura E Phelps
Journal:  J Smooth Muscle Res       Date:  2015

5.  Analysis of Geometric and Hemodynamic Profiles in Rat Arteriovenous Fistula Following PDE5A Inhibition.

Authors:  Hannah Northrup; Maheshika Somarathna; Savanna Corless; Isabelle Falzon; John Totenhagen; Timmy Lee; Yan-Ting Shiu
Journal:  Front Bioeng Biotechnol       Date:  2021-12-02

6.  Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil.

Authors:  Ulrich Dietz; Hans-Peter Tries; Walter Merkle; Cornelia Jaursch-Hancke; Heinz Lambertz
Journal:  Cardiovasc Diabetol       Date:  2003-08-04       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.